Acorda Therapeutics to Host Conference Call to Report Third Quarter 2006 Financial Results on November 2, 2006

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics (Nasdaq: ACOR) announced today that it will host a conference call on Thursday, November 2, 2006 at 8:30 a.m. Eastern Time to review the Company's third quarter 2006 financial results. The Company will issue a press release regarding its third quarter results on the same day, prior to the conference call.

To participate in the conference call, please dial 866-543-6407 (domestic) or 617-213-8898 (international) and reference the access code 94915046. A replay of the call will be available from 10:30 a.m. Eastern Time on November 2, 2006 until December 2, 2006 at midnight. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 39211037. A live audio webcast of the call and the archived webcast will be available for 30 days in the Investor Relations section of the Acorda website at http://www.acorda.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda's lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.